Google
AllShoppingImagesNews Maps Videos Books
Search tools
Archives
  • Recent
  • Past hour
  • Past 24 hours
  • Past week
  • Past month
  • Past year
  • Archives
Sorted by date
Clear

Gear Up for Pfizer (PFE) Q3 Earnings: Wall Street Estimates for Key Metrics

MSN
Wall Street analysts expect Pfizer (PFE) to post quarterly earnings of $0.64 per share in its upcoming report, which indicates a year-over-year increase of...
2 months ago

Anvisa aprova medicamentos inéditos para câncer renal e doença pulmonar

Prefeitura de São Paulo
A Anvisa aprovou o registro de dois medicamentos inéditos no Brasil que irão auxiliar no tratamento de um tipo de câncer no rim e de doenças pulmonares.
4 months ago

StockWatch: Pfizer Scales Patent Cliff by Pursuing Seagen Deal

Genetic Engineering and Biotechnology News
Pfizer's interest in acquiring Seagen stems from a need to recoup patent cliff revenue losses by replenishing its pipeline, analysts say.
22 months ago

Novartis, Pfizer, AZ and more hand China 50%-plus cancer drug discounts

FiercePharma
China is quickly approving many of the newest cancer drugs but it also is demanding big discounts if drugmakers want them on its national insurance coverage...
75 months ago

Bristol-Myers' Opdivo falls short at NICE, thanks to Pfizer's Inlyta discount

FiercePharma
England's cost-effectiveness watchdogs have a love-hate relationship with Opdivo, the hot Bristol-Myers Squibb immuno-oncology treatment.
102 months ago